Foundation for innovation
in Cardiometabolism and Nutrition

Support the MAS-HCC-PREDICT project

The MAS-HCC-PREDICT Project: Metabolic Dysfunction-Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma: Predictive Factors of Overall Survival and Disease Progression Compared to Other Cirrhosis Etiologies – A Retrospective and Prospective Cohort Study (PAIR-OBC)

Liver cancers, particularly hepatocellular carcinoma (HCC), are rapidly increasing and represent a major public health issue. They are often diagnosed late, which limits the possibilities for curative treatment.
CHC most often develops in a liver affected by cirrhosis, linked to hepatitis, alcohol, or metabolic alcoholic liver disease (MASLD), a rapidly growing disease associated with more severe forms.
This study aims to better understand the factors that influence survival and response to treatment in patients with HCC, particularly those related to MASLD, in order to improve patient management, treatment selection, and prognosis.

The main objective of this study is to identify the clinical, biological, and imaging factors associated with survival in patients with liver cancer (hepatocellular carcinoma) treated at the Pitié-Salpêtrière Hospital.
It also aims to determine the proportion of patients with metabolic hepatic steatosis (MASLD), compare disease progression, treatment efficacy, and adverse effects according to the origin of liver disease (metabolic, alcoholic, or viral), and to identify predictive markers of survival, disease progression, and response to treatment based on blood and tissue analyses.

This study will provide a better understanding of the factors influencing survival and response to treatment in patients with liver cancer.
It will contribute to more personalized care by tailoring treatment choices to the profile and cause of liver disease.
Ultimately, this should improve treatment effectiveness, reduce unnecessary side effects, and optimize follow-up care, with a direct benefit on patient prognosis and quality of life.